ImmuNext Inc.

1 Medical Center Drive
Lebanon
New Hampshire
03756
United States

Email: info@ImmuNext.com

Show jobs for this employer

About ImmuNext Inc.

ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Our lead product, anti-VISTA, is partnered with Janssen for the treatment of cancer and is currently in a Phase I clinical trial. Our second product, VISTA agonists, is partnered with Hoffmann-La Roche for the treatment of autoimmune diseases. Our third product, anti-CD40L, is partnered with Sanofi for the treatment of autoimmune diseases. Other programs include a CD40 agonist for neoantigen cancer vaccines and a novel immuno-metabolic target, in each case establishing new classes of compounds.
YEAR FOUNDED:
2011
LEADERSHIP:
CEO: David DeLucia
CSO: Randolph Noelle
JOBS:
Please click here for ImmuNext job opportunities.

3 articles about ImmuNext Inc.